Clinical Trials
Intensity Therapeutics Secures $6.6 Million to Advance Cancer Treatment Research
Intensity Therapeutics raises $6.6 million through an At-the-Market offering to fund clinical trials for its innovative cancer therapy, INT230-6, marking a significant step forward in the fight against cancer.
Intensity Therapeutics Raises $6.6 Million in July 2025 Through At-The-Market Stock Sales
Intensity Therapeutics, Inc. bolstered its financial position by securing $6.6 million through at-the-market stock sales, enabling further advancement of its innovative cancer therapy clinical trials.
Soligenix Inc. Advances in Treating Rare Skin Cancer with HyBryte Platform
Soligenix Inc.'s progress with its HyBryte platform for treating cutaneous T-cell lymphoma highlights the critical need for innovative therapies in addressing rare diseases among the aging population.
Oragenics Inc. Advances ONP-002 Phase IIa Trial with Southern Star Research for Concussion Treatment
Oragenics Inc. partners with Southern Star Research to conduct a Phase IIa trial for ONP-002, an intranasal therapy aimed at treating mild traumatic brain injuries, highlighting a significant step towards addressing the unmet needs in concussion care.
Soligenix Inc. Achieves Significant Milestone in Phase 2a Study for Behçet’s Disease Treatment
Soligenix Inc. reports promising results from its Phase 2a study of SGX945 for Behçet’s Disease, showing potential to address unmet medical needs in inflammatory conditions.
Lantern Pharma Achieves Milestone in Phase 2 HARMONIC Trial for Non-Smoker NSCLC Patients in Japan
Lantern Pharma completes targeted enrollment for its Phase 2 HARMONIC trial in Japan, marking a significant step in its international expansion and offering hope for never-smoker NSCLC patients.
Calidi Biotherapeutics Inc. Receives FDA Fast Track Designation for CLD-201 in Soft Tissue Sarcoma
Calidi Biotherapeutics Inc. has been granted FDA Fast Track designation for its CLD-201 treatment, marking a significant step forward in the development of therapies for soft tissue sarcoma and other cancers.
Scinai Immunotherapeutics Ltd. Announces Peer-Reviewed Data Supporting PC111 as Potential Disease Modifier
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has published peer-reviewed data in the Journal of Dermatological Treatment, highlighting PC111's potential as a disease modifier for pemphigus and SJS/TEN, offering a new, non-immunosuppressive treatment approach.
hyperCORE International Appoints Nicholas Focil as New President
Nicholas Focil's appointment as president of hyperCORE International signals a strategic move to enhance the network's global clinical research impact through his extensive experience in clinical operations and diversity in trials.
GeoVax Advances in Vaccine Development and Immunotherapy with Promising Clinical Data
GeoVax Labs reports significant progress in its vaccine and immunotherapy pipeline, including favorable regulatory guidance for GEO-MVA and robust immune responses from GEO-CM04S1 in CLL patients, highlighting the company's potential to address urgent medical needs.
Clene Inc. Advances Toward FDA Approval for ALS Treatment, Highlighting Market Potential
Clene Inc. is making significant progress toward FDA accelerated approval for its ALS drug CNM-Au8®, targeting a $1.3 billion market by 2034 with a novel approach to neurodegenerative diseases.
American Heart Association Expands Initiative to Combat Cardiovascular-Kidney-Metabolic Syndrome Across 15 U.S. Regions
The American Heart Association's expansion of its Cardiovascular-Kidney-Metabolic Health Initiative to 15 U.S. regions aims to address the interconnected conditions leading to heart disease and stroke, marking a significant step in public health intervention.
Lexaria's DehydraTECH-Semaglutide Shows Promising Reduction in Side Effects Compared to Rybelsus®
Lexaria Bioscience Corp. reports interim results from its Phase 1b study, showing DehydraTECH-semaglutide significantly reduces gastrointestinal and overall side effects compared to Rybelsus®, potentially improving patient adherence to treatment.
Soligenix Inc. Advances Treatment for Rare Behçet’s Disease with SGX945
Soligenix Inc. is developing SGX945, a promising treatment for Behçet’s disease, addressing the critical need for more effective therapies for this rare condition.
Clene Inc. Advances Neurodegenerative Disease Treatment with FDA-Backed Biomarker Analysis
Clene Inc. is set to initiate neurofilament biomarker analyses for its drug CNM-Au8 in ALS patients, marking a significant step towards innovative treatments for neurodegenerative diseases.
Soligenix Inc. Advances in Oral Mucositis Treatment with SGX942
Soligenix Inc. is making strides with SGX942, a novel treatment for severe oral mucositis, showing promise in reducing the condition's severity and duration in cancer patients.
GeoVax Shifts Gedeptin® Strategy to Neoadjuvant Combination Trial After KEYNOTE-689 Success
GeoVax Labs, Inc. announces a strategic pivot in its Gedeptin® clinical development program towards a neoadjuvant therapy combination with pembrolizumab for head and neck squamous cell carcinoma, following promising KEYNOTE-689 Phase 3 trial results.
NanoViricides' NV-387 Shows Promise as Broad-Spectrum Antiviral with Strategic Pandemic Preparedness Value
NanoViricides, Inc. highlights NV-387's broad antiviral potential and its strategic importance for pandemic preparedness, with plans for a Phase II trial targeting MPox.
Lantern Pharma Reports First Complete Response in Phase 1 LP-284 Trial for Aggressive DLBCL
Lantern Pharma's LP-284 shows promising results in a Phase 1 trial for aggressive DLBCL, marking a significant step forward in the treatment of refractory lymphomas.
Experimental mRNA Vaccine Shows Promise in Enhancing Cancer Immunotherapy
Researchers have discovered that an experimental mRNA vaccine could significantly improve the effectiveness of immunotherapy in fighting tumors, marking a potential advancement towards universal cancer vaccines.
Dr. Matt Kaeberlein on Bridging the Gap Between Longevity Research and Clinical Practice
Dr. Matt Kaeberlein discusses the transition from academic research to clinical application in longevity science through Optispan, emphasizing evidence-based health optimization.
NanoViricides Announces Promising Results for Measles Treatment in Humanized Animal Study
NanoViricides, Inc. reports a significant breakthrough with its lead drug candidate, NV-387, showing increased survival rates in a lethal measles infection model, highlighting the potential for the first therapeutic option amid rising global measles cases.
GeoVax Advances Toward European Approval for Mpox Vaccine Following EMA Guidance
GeoVax Labs, Inc. has received positive Scientific Advice from the European Medicines Agency, paving the way for expedited approval of its GEO-MVA Mpox vaccine in the EU, potentially accelerating revenue generation.
Soligenix Inc. Reports Promising Results in HyBryte(TM) Trial for Early-Stage Cutaneous T-Cell Lymphoma
Soligenix Inc.'s HyBryte(TM) shows promising treatment success in early-stage cutaneous T-cell lymphoma, offering hope for patients with limited options.
FDA Grants RMAT Designation to GNSC-001 for Knee Osteoarthritis Treatment
The FDA's RMAT designation for GNSC-001 highlights its potential as a groundbreaking gene therapy for knee osteoarthritis, offering long-term relief with a single injection.
Modified Herpes Virus Shows Promise in Treating Advanced Melanoma
A recent study indicates that a genetically altered herpes virus could offer a new treatment avenue for advanced melanoma, highlighting the potential of oncolytic viruses in cancer therapy.
Oragenics Inc. Secures U.S. Manufacturing Partner for Concussion Drug Ahead of Phase IIb Trials
Oragenics Inc. has partnered with Sterling Pharma Solutions for the GMP production of its concussion drug candidate, ONP-002, marking a significant step towards Phase IIb trials and underscoring the importance of domestic manufacturing in clinical development.
BioRestorative Therapies Reports Promising Phase 2 Trial Results for Chronic Pain Treatment
BioRestorative Therapies' phase 2 trial results for BRTX-100 show significant improvement in function and pain reduction for chronic lumbar disc disease patients, potentially paving the way for accelerated FDA approval.
GeoVax Advances Mpox Vaccine Development Amid Global Outbreak Concerns
GeoVax Labs accelerates its GEO-MVA vaccine candidate development following EMA's streamlined approval pathway, addressing the urgent need for diversified Mpox vaccine supply as global outbreaks expand.
Kairos Pharma Ltd. Reports Positive Safety Results in Phase 2 Study of Prostate Cancer Drug ENV-105
Kairos Pharma Ltd. announces favorable interim safety results from its Phase 2 trial of ENV-105 for metastatic castration-resistant prostate cancer, marking a significant step forward in cancer therapy.